The University of Chicago Header Logo

Connection

Theodore Karrison to Benzimidazoles

Back to Details
This is a "connection" page, showing publications Theodore Karrison has written about Benzimidazoles.
Theodore Karrison
Connection Strength
0.590
Benzimidazoles
  1. University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL. Br J Haematol. 2018 04; 181(2):264-267.
    View in: PubMed
    Score: 0.493
  2. Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res. 2014 Jan 15; 20(2):490-8.
    View in: PubMed
    Score: 0.097
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.